Abstract:Background Reserpine (RES), a Vesicular Monoamine Transporter 2 (VMAT 2 ) inhibitor agent, has been used in preclinical research for many years to create animal models for depression and to test experimental antidepressant strategies. Nevertheless, evidence of the potential use and validity of RES as a chronic pharmacological model for depression is lacking, and there are no comprehensive studies of the behavioral effects in conjunction with molecular outcomes. Methods Experiment 1. Following baseline behavior testing sensitive to depression-like phenotype and locomotion (Phase 1), 27 Sprague-Dawley (SD) rats received i.p. either vehicle solution (0.0 mg/kg), low (0.2 mg/kg) or high (0.8 mg/kg) RES dose for 20 days using a pre-determined schedule and reassessed for behavioral phenotypes (Phase 2). After 10 days washout period, and a final behavioral assessment (Phase 3), the brains were collected 16 days after the last injection for mRNA-expression assessment. Experiment 2. In a similar timetable as in Experiment 1 but without the behavioral testing, 12 SD rats underwent repetitive dopamine D 2/3 receptor PET scanning with [ 18 F]DMFP following each Phase. The binding potential ( BP ND ) of [ 18 F]DMFP was quantified by kinetic analysis as a marker of striatal D 2/3 R availability. Weight and welfare were monitored throughout the study. Results Significant, dose-dependent weight loss and behavioral deficits including both motor (hypo-locomotion) and non-motor behavior (anhedonia, mild anxiety and reduced exploration) were found for both the low and high dose groups with significant decrease in D 2 R mRNA expression in the accumbal region for the low RES group after Phase 3. Both RES treated groups showed substantial increase in [ 18 F]DMFP BP ND (in line with dopamine depletion) during Phase 2 and 3 compared to baseline and Controls. Conclusions The longitudinal design of the study demonstrated that chronic RES administration induced striatal dopamine depletion that persisted even after the wash-out period. However, the behavior phenotype observed were transient. The data suggest that RES administration can induce a rodent model for depression with mild face validity.

Propargyl-Assisted Selective Amidation Applied in C-terminal Glycine Peptide Conjugation.

Effect of a New Substance with Pyridoindole Structure on Adult Neurogenesis, Shape of Neurons, and Behavioral Outcomes in a Chronic Mild Stress Model in Rats

Mir-16 and Fluoxetine Both Reverse Autophagic and Apoptotic Change in Chronic Unpredictable Mild Stress Model Rats.

Reserpine-induced rat model for depression: Behavioral, physiological and PET-based dopamine receptor availability validation

Preclinical models of treatment-resistant depression: challenges and perspectives

Scaling up from greenhouse resistance to fitness in the field for a host of an emerging forest disease

Spectra of data sampled at frequency-modulated rates in application to cardiovascular signals: Part 1 analytical derivation of the spectra

Behavioural characteristics and sex differences of a treatment-resistant depression model: Chronic mild stress in the Wistar-Kyoto rat

Sildenafil, alone and in combination with imipramine or escitalopram, display antidepressant-like effects in an adrenocorticotropic hormone-induced (ACTH) rodent model of treatment-resistant depression

Chronic unpredictable mild stress paradigm in male Wistar rats: effect on anxiety- and depressive-like behavior

The antidepressant effects and serum metabonomics of bifid triple viable capsule in a rat model of chronic unpredictable mild stress

What to do about orchestrated email campaigns

Citalopram Counteracts Depressive-Like Symptoms Evoked by Chronic Social Stress in Rats

AMPA receptors mediate the pro-cognitive effects of electrical and optogenetic stimulation of the medial prefrontal cortex in antidepressant non-responsive Wistar-Kyoto rats

The selective 5-HT1A receptor biased agonists, F15599 and F13714, show antidepressant-like properties after a single administration in the mouse model of unpredictable chronic mild stress

Treatment response of venlafaxine induced alterations of gut microbiota and metabolites in a mouse model of depression

Nickel and chromium levels in the saliva and serum of patients with fixed orthodontic appliances.

Using tests and models to assess antidepressant-like activity in rodents

Strategies for Treatment-Resistant Depression: Lessons Learned from Animal Models

Treatment-resistant depression: are animal models of depression fit for purpose?

The opposite effect of a 5-HT1B receptor agonist on 5-HT synthesis, as well as its resistant counterpart, in an animal model of depression